Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
KTN3379 · 3 trials · 3 indications
Reduction in pErbB3 levels
Continued assessment of safety
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | Treatment with KTN3379 in HPV positive head and neck cancer patients |
| B | EXPERIMENTAL | Treatment with KTN3379 in HPV negative head and neck cancer patients |
| Combination of Vemurafenib and KTN3379 | EXPERIMENTAL | Vemurafenib 960 mg po bid KTN3379 1000 mg IV q2weeks |
| KTN3379 | EXPERIMENTAL | KTN3379 |
| Part II, Arm A | EXPERIMENTAL | Combination of KTN3379 and cetuximab |
| Part II, Arm B | EXPERIMENTAL | Combination of KTN3379 and erlotinib |
| Part II, Arm C | EXPERIMENTAL | Combination of KTN3379 and vemurafenib |
| Part II, Arm D | EXPERIMENTAL | Combination of KTN3379 and trastuzumab |
| Name | Type | Description |
|---|---|---|
| KTN3379 | BIOLOGICAL | - |
| vemurafenib | DRUG | 960 mg po bid |
Inclusion Criteria: 1. Histologically or cytologically confirmed primary, untreated SCCHN including variants. Patients must be candidates for surgical resection. Primary tumors of oral cavity, oropharynx, hypopharnyx or larynx are included. 2. Written informed consent and any locally required autho...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
KTN3379 is an investigational monoclonal antibody being studied for use in oncology, specifically for advanced cancer, squamous cell carcinoma of the head and neck, and thyroid cancer. It is being developed by Celldex Therapeutics, Inc. (CLDX) and is currently in Phase 1 clinical development.
KTN3379 is a monoclonal antibody, but its specific molecular target has not been disclosed in the available information. The drug is being investigated for its potential role in treating certain cancers, including head and neck squamous cell carcinoma and thyroid cancer.
KTN3379 is being developed by Celldex Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol CLDX. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in patients with advanced tumors.
KTN3379 is in Phase 1 clinical development. All three clinical trials listed for this drug are Phase 1 studies, and they have all been completed. The drug is investigational and has not been approved by regulatory authorities for any indication.
KTN3379 has been studied in three completed Phase 1 clinical trials: NCT02014909, a safety and pharmacokinetics study in adults with advanced tumors; NCT02456701, a study combining vemurafenib and KTN3379 in BRAF mutant thyroid cancer; and NCT02473731, a window of opportunity study in surgically resectable head and neck cancer patients.
KTN3379 is not known to have any alternative names. It is a distinct investigational monoclonal antibody developed by Celldex Therapeutics, Inc. for potential use in treating certain types of cancer, including head and neck squamous cell carcinoma and thyroid cancer.